Ovid and Angelini Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize…
Ovid Therapeutics Inc. and Angelini Pharma S.p.A. announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the…
Read More...
Read More...
